The corporate-backed pharmaceutical company has postponed an initial public offering for the second time, a week after it set the terms.
US-based biopharmaceutical company Viamet Pharmaceuticals has withdrawn an initial public offering that would have granted exits to pharmaceutical firms Eli Lilly, Novartis and Astellas.
Viamet set the range for the IPO between $14 and $16 per share last week, and would have raised $91.2m if it had floated at the top of its range. It also postponed a $75m IPO in July 2014, instead opting to raise $60m in equity funding.
The company is developing metalloenzyme treatments for conditions…
